急性缺血性卒中血液/脑谷氨酸捕获的临床验证
该转化研究通过体外高通量筛选1120种化合物发现核黄素(维生素B2)为血液谷氨酸捕获剂主要命中化合物,并在缺血动物模型中证实核黄素(1mg/kg)降低血液谷氨酸与梗死体积显著减小相关;随后在50例卒中患者中开展随机双盲IIb期临床试验,核黄素20mg组谷氨酸浓度下降显著大于安慰剂组(p<0.029),出院时NIHSS评分改善百分比核黄素组略高于安慰剂组(33.7±43.7% vs 48.9±42.4%,p=0.050)。
要点
- 体外高通量筛选1120种化合物,核黄素被确定为主要命中化合物。
- 缺血动物模型给予核黄素1mg/kg,血液谷氨酸降低与梗死体积显著减小相关。
- 50例卒中患者随机双盲IIb期试验中,核黄素20mg组谷氨酸浓度下降显著大于安慰剂组(p<0.029)。
核心结论
- 该转化研究首次在人体中证明血液谷氨酸捕获剂治疗卒中患者的疗效,为开发一种有前景的新型保护性疗法开辟了道路。
研究设计与样本
- 研究采用药物重定位策略,先进行体外高通量筛选评估1120种化合物(其中90%为美国食品药品监督管理局批准的药物)的谷氨酸捕获能力,再在缺血动物模型中验证所选药物的保护效力,最后在卒中患者中进行随机双盲IIb期临床试验。
- 临床试验共随机分配50例卒中患者至两个研究组:对照组(安慰剂)和实验组(核黄素20mg)。
主要发现
- 核黄素(维生素B2)被确定为主要命中化合物。
- 在缺血动物模型中,核黄素(1mg/kg)治疗确认血液谷氨酸降低与梗死体积显著减小相关。
- 临床试验中,核黄素治疗组谷氨酸浓度下降显著大于安慰剂组(p<0.029)。
- 出院时美国国立卫生研究院卒中量表评分改善百分比核黄素治疗组略高于安慰剂组(33.7±43.7% vs 48.9±42.4%,p=0.050)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Blood/brain-glutamate grabbing is an emerging concept in the treatment of acute ischemic stroke, where essentially the deleterious effects of glutamate after ischemia are ameliorated by coaxing glutamate to enter the bloodstream and thus reducing its concentration in the brain. Aiming to demonstrate the clinical efficacy of blood glutamate grabbers in patients with stroke, in this study, we resorted to a drug-repositioning strategy for the discovery of new glutamate-grabbing drugs. METHODS: The glutamate-grabbing ability of 1,120 compounds (90% of which were drugs approved by the US Food and Drug Administration) was evaluated during an in vitro high-throughput screening campaign. Subsequently, the protective efficacy of the selected drugs was probed in an ischemic animal model and finally tested in stroke patients. RESULTS: Riboflavin (vitamin B2 ) was identified as the main hit compound. In ischemic animal models treated with riboflavin (1mg/kg), it was confirmed that blood glutamate reduction was associated with a significant reduction of infarct size. These results led to a randomized, double-blind, phase IIb clinical trial with patients with stroke. Fifty patients were randomized to 1 of the 2 study arms: the control group (placebo) and the experimental group (20mg of riboflavin [vitamin B2 Streuli@ ). Decrease in glutamate concentration was significantly greater (p < 0.029) in the treated group. Comparative analysis of the percentage improvement on the National Institutes of Health Stroke Scale score at discharge was slightly higher in the riboflavin-treated group than in the placebo group (33.7 ± 43.7 vs 48.9 ± 42.4%, p = 0.050). INTERPRETATION: This translational study represents the first human demonstration of the efficacy of blood glutamate grabbers in the treatment of patients with stroke, paving the way for the development of a promising novel protective therapy. Ann Neurol 2018;84:260-273.
引用
- da Silva-Candal A, Pérez-Díaz A, Santamaría M, et al. Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke. Ann Neurol. 2018. PMID: 30014516. doi:10.1002/ana.25286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。